I agree that this site is using cookies. You can find further informations here.
X
Al, Maiwenn
854  results:
Search for persons X
?
1

Evaluating the Validation Process: Embracing Complexity and..:

Corro Ramos, Isaac ; Feenstra, Talitha ; Ghabri, Salah.
PharmacoEconomics.  42 (2024)  7 - p. 715-719 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Being Transparent About Brilliant Failures: An Attempt to U..:

Holleman, Marscha S. ; Huygens, Simone A. ; Al, Maiwenn J....
Drugs - Real World Outcomes.  9 (2022)  2 - p. 275-285 , 2022
Link: https://doi.org/10.1007/..
 
?
3

Home Telemonitoring and a Diagnostic Algorithm in the Manag..:

Albuquerque de Almeida, Fernando ; Corro Ramos, Isaac ; Al, Maiwenn.
JMIR Cardio.  6 (2022)  2 - p. e31302 , 2022
Link: https://doi.org/10.2196/..
 
?
4

Model-based cost-effectiveness analyses comparing combinati..:

van de Laar, Celine Johanna ; Janssen, Carly A. ; Janssen, Matthijs...
PLOS ONE.  17 (2022)  1 - p. e0261940 , 2022
Link: https://doi.org/10.1371/..
 
?
5

Real‐world evidence in health technology assessment of high..:

Klein, Philip ; Blommestein, Hedwig ; Al, Maiwenn...
Health Economics.  31 (2022)  S1 - p. 10-24 , 2022
Link: https://doi.org/10.1002/..
 
?
6

The Man in the Hat:

Davidson, John-Paul ; Hinds, Ciarán ; Maïwenn. , 2021
Link: https://unibremen.kanopy..
 
?
7

Modeling Early Warning Systems: Construction and Validation..:

Albuquerque de Almeida, Fernando ; Corro Ramos, Isaac ; Rutten-van Mölken, Maureen.
Value in Health.  24 (2021)  10 - p. 1435-1445 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Quo Vadis HTA for Medical Devices in Central and Eastern Eu..:

Daubner-Bendes, Rita ; Kovács, Sándor ; Niewada, Maciej...
Frontiers in Public Health.  8 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
9

Impact of hospitalisation on health-related quality of life..:

Albuquerque de Almeida, Fernando ; Al, Maiwenn J. ; Koymans, Ron...
Health and Quality of Life Outcomes.  18 (2020)  1 - p. , 2020
Link: https://doi.org/10.1186/..
 
?
10

Cost-effectiveness analysis of the first-line EGFR-TKIs in ..:

Holleman, Marscha S. ; Al, Maiwenn J. ; Zaim, Remziye..
The European Journal of Health Economics.  21 (2020)  1 - p. 153-164 , 2020
Link: https://www.jstor.org/st..
 
?
11

Phase I/II Clinical Trial-Based Early Economic Evaluation o..:

Vreman, Rick A. ; Geenen, Joost W. ; Hövels, Anke M....
Applied Health Economics and Health Policy.  17 (2019)  6 - p. 883-893 , 2019
Link: https://doi.org/10.1007/..
 
?
12

TECH-VER: A Verification Checklist to Reduce Errors in Mode..:

Büyükkaramikli, Nasuh C. ; Rutten-van Mölken, Maureen P. M. H. ; Severens, Johan L..
PharmacoEconomics.  37 (2019)  11 - p. 1391-1408 , 2019
Link: https://doi.org/10.1007/..
 
?
13

First-line tyrosine kinase inhibitors in EGFR mutation-posi..:

Holleman, Marscha S ; van Tinteren, Harm ; Groen, Harry J M..
OncoTargets and Therapy.  12 (2019)  - p. 1413-1421 , 2019
Link: https://doi.org/10.2147/..
 
?
14

Cost-effectiveness analysis of the first-line EGFR-TKIs in ..:

Holleman, Marscha S. ; Al, Maiwenn J. ; Zaim, Remziye..
The European Journal of Health Economics.  21 (2019)  1 - p. 153-164 , 2019
Link: https://doi.org/10.1007/..
 
?
15

Conceptual model for the health technology assessment of cu..:

Alemao, Evo ; Al, Maiwenn J. ; Boonen, Annelies A....
PLOS ONE.  13 (2018)  10 - p. e0205013 , 2018
Link: https://doi.org/10.1371/..
 
1-15